This study is examining if a medicine called **siplizumab** can help patients accept a new kidney without rejecting it. **Siplizumab** is a type of medicine (a monoclonal antibody) that targets specific cells in the body to prevent rejection. The study compares it to another medicine called **rabbit anti-thymocyte globulin (rATG)**, which is also used to help the body accept a transplant. Participants will receive either siplizumab or rATG, along with standard anti-rejection medicines. They will be monitored for a year after their kidney transplant surgery. The study will check how the body reacts to these medicines and how well the new kidney works. Participants need to visit the study site for check-ups and provide medical history and blood samples. **Key Points:** - Study lasts for 12 months with regular follow-up visits. - Participants receive either siplizumab or rATG plus regular anti-rejection drugs. - Eligibility includes having a kidney transplant from a matching donor and meeting specific health criteria.

Study Overview

This study examines if siplizumab can help patients accept a new kidney without rejecting it. Siplizumab targets specific cells to prevent rejection. It's compared to another medicine, rabbit anti-thymocyte globulin (rATG).

Participants will receive either siplizumab or rATG, with standard anti-rejection medicines. They will be monitored for a year after their kidney transplant surgery. The study checks how the body reacts to these medicines and how well the new kidney works.

Key Points:

• Study lasts for 12 months with regular follow-up visits.
• Participants receive either siplizumab or rATG plus regular anti-rejection drugs.
• Eligibility includes having a kidney transplant from a matching donor and meeting specific health criteria.